A recent double‐blind, randomized, placebo‐controlled trial (EXIST‐3) showed that mTOR inhibitor, everolimus, was significantly more effective than placebo in reducing focal seizures in TSC patients with drug‐resistant epilepsy.35 Here, MTOR is linked to tuberous sclerosis.